Roflumilast (Daliresp®) to reduce acute pulmonary events in fibrotic sarcoidosis: a multi-center, double blind, placebo controlled, randomized clinical trial

BACKGROUND: Fibrotic sarcoidosis patients often have acute events of increased cough and sputum production. We evaluated the impact of roflumilast in fibrotic sarcoidosis patients with repeated episodes of increased cough and sputum. METHODS: Sarcoidosis patients with pulmonary fibrosis and at least...

Descripción completa

Detalles Bibliográficos
Autores principales: Baughman, Robert P, Judson, Marc A, Culver, Daniel A, Birring, Surinder S, Parambil, Joseph, Zeigler, Joyce, Lower, Elyse E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mattioli 1885 2021
Materias:
Original Article: Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8552567/
https://www.ncbi.nlm.nih.gov/pubmed/34744427
http://dx.doi.org/10.36141/svdld.v38i3.11684

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8552567/
https://www.ncbi.nlm.nih.gov/pubmed/34744427
http://dx.doi.org/10.36141/svdld.v38i3.11684

Ejemplares similares